Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (G7)

Pulmonary hypertension (PH) is a devastating disease characterized by high blood pressure that affects the pulmonary arteries and the right side of the heart leading to substantial morbidity and mortality. There is no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs approved for PH are considerable, driven by premium pricing and the likelihood of polypharmacy. Although this therapy market has become congested, commercial interest in PH remains high owing to the need for more efficacious, disease-modifying agents, as well as the lack of approved treatments for underserved populations.

Questions answered

• What are the views of KOLs regarding Merck & Co.’s sotatercept, which has a unique nonvasodilatory mechanism of action? How will the launch of this agent affect prescribing decisions?
• Novel agents such as United Therapeutics’ ralinepag and Gossamer Bio’s seralutinib are in late-phase development for PH. What do KOLs say about the advantages and disadvantages of these therapies?
• Generic formulations of several key branded therapies have launched for PH in recent years. How have these launches impacted prescribing patterns? What effect have generic launches had on entrenched brands, and how will they affect the performance of emerging therapies?
• The treatment of PH WHO groups 2, 3, and 5 is characterized by substantial unmet need. What are the other key unmet needs in PH? How likely are these unmet needs to be fulfilled during the forecast period?

Geography: United States, EU5, Japan

Primary research: 29 country-specific interviews with thought-leading cardiologists and pulmonologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Diagnosed prevalence of PH by country, cause of the disease and drug-treated rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key PH therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.